Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia

Molecular Psychiatry

Volumn 18, Issue 11, 2013, Pages 1185-1192

  Weickert, C S ^a,b,c   Fung, S J ^a,b,c   Catts, V S ^a,b,c   Schofield, P R ^a,b,c   Allen, K M ^a,b,c   Moore, L T ^b   Newell, K A ^a,d   Pellen, D ^b   Huang, X F ^a,d   Catts, S V ^b,e   Weickert, T W ^a,b,c  

^a Schizophrenia Research Institute   (Australia)

^b NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF WOLLONGONG   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cognition; Expression; NMDA receptor; Prefrontal cortex; Schizophrenia; SNP

Indexed keywords

MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2C; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 3A; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; STOICHIOMETRY;

ADULT; ALLELES; CASE-CONTROL STUDIES; COGNITION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PREFRONTAL CORTEX; PROTEIN SUBUNITS; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; WECHSLER SCALES;

EID: 84888307727     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2012.137     Document Type: Article

References (75)

1. Weickert TW Goldberg TE, Gold JM, Bigelow LB, Egan MF, Weinberger DR. Cognitive impairments in patients with schizophrenia displaying preserved and compromised intellect. Arch Gen Psychiatry 2000; 57: 907-913
2. Catts V, Catts S. The psychotomimetic effects of PCP, LSD and Ecstacy: Pharmacological models of schizophreniä In: Sachdev P, Keshavan M (eds). Secondary Schizophrenia. Cambridge University Press: Cambridge, 2010
3. Gilmour G, Dix S, Fellini L, Gastambide F, Plath N, Steckler T et al. NMDA receptors, cognition and schizophrenia-Testing the validity of the NMDA receptor hypofunction hypothesis. Neuropharmacology 2012; 63: 1401-1412
4. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148: 1301-1308
5. Kantrowitz JT, Javitt DC. Thinking glutamatergically: Changing concepts of schizophrenia based upon changing neurochemical models. Clin Schizophr Relat Psychoses 2010; 4: 189-200
6. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51: 199-214
7. Lahti AC, Koffel B, LaPorte D, Tamminga CA. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995; 13: 9-19
8. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R. Study of a new schizophrenomimetic drug; sernyl. AMA Arch Neurol Psychiatry 1959; 81: 363-369
9. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D et al. Ketamineinduced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997; 17: 141-150
10. Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N et al. Decreased serum levels of D-serine in patients with schizophrenia: Evidence in support of the N-methyl-D-Aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 2003; 60: 572-576
11. Madeira C, Freitas ME, Vargas-Lopes C, Wolosker H, Panizzutti R. Increased brain D-Amino acid oxidase (DAAO) activity in schizophrenia. Schizophr Res 2008; 101: 76-83
12. Schultz CC, Nenadic I, Koch K, Wagner G, Roebel M, Schachtzabel C et al. Reduced cortical thickness is associated with the glutamatergic regulatory gene risk variant DAOA Arg30Lys in schizophrenia. Neuropsychopharmacology 2011; 36: 1747-1753
13. Moghaddam B, Javitt D. From revolution to evolution: The glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 2012; 37: 4-15
14. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK et al. Glutamate receptor ion channels: Structure, regulation, and function. Pharmacol Rev 2010; 62: 405-496
15. Itokawa M, Yamada K, Yoshitsugu K, Toyota T, Suga T, Ohba H et al. A microsatellite repeat in the promoter of the N-methyl-D-Aspartate receptor 2A subunit (GRIN2A) gene suppresses transcriptional activity and correlates with chronic outcome in schizophrenia. Pharmacogenetics 2003; 13: 271-278
16. Iwayama-Shigeno Y, Yamada K, Itokawa M, Toyota T, Meerabux JM, Minabe Y et al. Extended analyses support the association of a functional (GT)n polymorphism in the GRIN2A promoter with Japanese schizophrenia. Neurosci Lett 2005; 378: 102-105
17. Martucci L, Wong AH, De Luca V, Likhodi O, Wong GW, King N et al. N-methyl-Daspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: Polymorphisms and mRNA levels. Schizophr Res 2006; 84: 214-221
18. Miyatake R, Furukawa A, Suwaki H. Identification of a novel variant of the human NR2B gene promoter region and its possible association with schizophrenia. Mol Psychiatry 2002; 7: 1101-1106
19. Ohtsuki T, Sakurai K, Dou H, Toru M, Yamakawa-Kobayashi K, Arinami T. Mutation analysis of the NMDAR2B (GRIN2B) gene in schizophrenia. Mol Psychiatry 2001; 6: 211-216
20. Qin S, Zhao X, Pan Y, Liu J, Feng G, Fu J et al. An association study of the N-methyl-D-Aspartate receptor NR1 subunit gene (GRIN1) and NR2B subunit gene (GRIN2B) in schizophrenia with universal DNA microarray. Eur J Hum Genet 2005; 13: 807-814
21. Tang J, Chen X, Xu X, Wu R, Zhao J, Hu Z et al. Significant linkage and association between a functional (GT)n polymorphism in promoter of the N-methyl-Daspartate receptor subunit gene (GRIN2A) and schizophrenia. Neurosci Lett 2006; 409: 80-82
22. Zhao X, Li H, Shi Y, Tang R, Chen W, Liu J et al. Significant association between the genetic variations in the 5' end of the N-methyl-D-Aspartate receptor subunit gene GRIN1 and schizophrenia. Biol Psychiatry 2006; 59: 747-753
23. Beneyto M, Meador-Woodruff JH. Lamina-specific abnormalities of NMDA receptor-Associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder. Neuropsychopharmacology 2008; 33: 2175-2186
24. Law AJ, Deakin JF. Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. Neuroreport 2001; 12: 2971-2974
25. Humphries C, Mortimer A, Hirsch S, de Belleroche J. NMDA receptor mRNA correlation with antemortem cognitive impairment in schizophrenia. Neuroreport 1996; 7: 2051-2055
26. Sokolov BP. Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of 'neuroleptic-free' schizophrenics: Evidence on reversible up-regulation by typical neuroleptics. J Neurochem 1998; 71: 2454-2464
27. Dracheva S, Marras SA, Elhakem SL, Kramer FR, Davis KL, Haroutunian V. N-methyl-D-Aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia. Am J Psychiatry 2001; 158: 1400-1410
28. Schmitt A, Koschel J, Zink M, Bauer M, Sommer C, Frank J et al. Gene expression of NMDA receptor subunits in the cerebellum of elderly patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci 2010; 260: 101-111
29. Akbarian S, Sucher NJ, Bradley D, Tafazzoli A, Trinh D, Hetrick WP et al. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci 1996; 16: 19-30
30. Bickel S, Lipp HP, Umbricht D. Impaired attentional modulation of auditory evoked potentials in N-methyl-D-Aspartate NR1 hypomorphic mice. Genes Brain Behav 2007; 6: 558-568
31. Duncan G, Miyamoto S, Gu H, Lieberman J, Koller B, Snouwaert J. Alterations in regional brain metabolism in genetic and pharmacological models of reduced NMDA receptor function. Brain Res 2002; 951: 166-176
32. Duncan GE, Moy SS, Perez A, Eddy DM, Zinzow WM, Lieberman JA et al. Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function. Behav Brain Res 2004; 153: 507-519
33. Dzirasa K, Ramsey AJ, Takahashi DY, Stapleton J, Potes JM, Williams JK et al. Hyperdopaminergia and NMDA receptor hypofunction disrupt neural phase signaling. J Neurosci 2009; 29: 8215-8224
34. Halene TB, Ehrlichman RS, Liang Y, Christian EP, Jonak GJ, Gur TL et al. Assessment of NMDA receptor NR1 subunit hypofunction in mice as a model for schizophrenia. Genes Brain Behav 2009; 8: 661-675
35. Mohn AR, Gainetdinov RR, Caron MG, Koller BH. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999; 98: 427-436
36. Belforte JE, Zsiros V, Sklar ER, Jiang Z, Yu G, Li Y et al. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci 2010; 13: 76-83
37. Hawasli AH, Benavides DR, Nguyen C, Kansy JW, Hayashi K, Chambon P et al. Cyclin-dependent kinase 5 governs learning and synaptic plasticity via control of NMDAR degradation. Nat Neurosci 2007; 10: 880-886
38. Niewoehner B, Single FN, Hvalby O, Jensen V, Meyer zum Alten Borgloh S, Seeburg PH et al. Impaired spatial working memory but spared spatial reference memory following functional loss of NMDA receptors in the dentate gyrus. Eur J Neurosci 2007; 25: 837-846
39. Rampon C, Tang YP, Goodhouse J, Shimizu E, Kyin M, Tsien JZ. Enrichment induces structural changes and recovery from nonspatial memory deficits in CA1 NMDAR1-knockout mice. Nat Neurosci 2000; 3: 238-244
40. Tsien JZ, Huerta PT, Tonegawa S. The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory. Cell 1996; 87: 1327-1338
41. von Engelhardt J, Doganci B, Jensen V, Hvalby O, Gongrich C, Taylor A et al. Contribution of hippocampal and extra-hippocampal NR2B-containing NMDA receptors to performance on spatial learning tasks. Neuron 2008; 60: 846-860
42. Zhao MG, Toyoda H, Lee YS, Wu LJ, Ko SW, Zhang XH et al. Roles of NMDA NR2B subtype receptor in prefrontal long-Term potentiation and contextual fear memory. Neuron 2005; 47: 859-872
43. Ludwig KU, Roeske D, Herms S, Schumacher J, Warnke A, Plume E et al. Variation in GRIN2B contributes to weak performance in verbal short-Term memory in children with dyslexia. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 503-511
44. Turic D, Langley K, Mills S, Stephens M, Lawson D, Govan C et al. Follow-up of genetic linkage findings on chromosome 16p13: Evidence of association of N-methyl-D aspartate glutamate receptor 2A gene polymorphism with ADHD. Mol Psychiatry 2004; 9: 169-173
45. Weickert CS, Sheedy D, Rothmond DA, Dedova I, Fung S, Garrick T et al. Selection of reference gene expression in a schizophrenia brain cohort. Aust N Z J Psychiatry 2010; 44: 59-70
46. Wechsler D. Wechsler Adult Intelligence Scale. The Psyhological Corporation: San Antonio, TX 1997
47. Wechsler D. Wechsler Test of Adult Reading. The Psychological Corporation: San Antonio, TX 2001
48. Kristiansen LV, Bakir B, Haroutunian V, Meador-Woodruff JH. Expression of the NR2B-NMDA receptor trafficking complex in prefrontal cortex from a group of elderly patients with schizophrenia. Schizophr Res 2010; 119: 198-209
49. Kristiansen LV, Beneyto M, Haroutunian V, Meador-Woodruff JH. Changes in NMDA receptor subunits and interacting PSD proteins in dorsolateral prefrontal and anterior cingulate cortex indicate abnormal regional expression in schizophrenia. Mol Psychiatry 2006; 11: 737-747
50. Kornhuber J, Mack-Burkhardt F, Riederer P, Hebenstreit GF, Reynolds GP, Andrews HB et al. [3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients. J Neural Transm 1989; 77: 231-236
51. Simpson MD, Slater P, Royston MC, Deakin JF. Alterations in phencyclidine and sigma binding sites in schizophrenic brains. Effects of disease process and neuroleptic medication. Schizophr Res 1991; 6: 41-48
52. Nudmamud S, Reynolds GP. Increased density of glutamate/N-methyl-D- Aspartate receptors in superior temporal cortex in schizophrenia. Neurosci Lett 2001; 304: 9-12
53. Dean B, Hussain T, Hayes W, Scarr E, Kitsoulis S, Hill C et al. Changes in serotonin2A and GABA(A) receptors in schizophrenia: Studies on the human dorsolateral prefrontal cortex. J Neurochem 1999; 72: 1593-1599
54. Dean B, Pavey G, McLeod M, Opeskin K, Keks N, Copolov D. A change in the density of [(3)H]flumazenil, but not [(3)H]muscimol binding, in Brodmann's Area 9 from subjects with bipolar disorder. J Affect Disord 2001; 66: 147-158
55. Noga JT, Hyde TM, Herman MM, Spurney CF, Bigelow LB, Weinberger DR et al. Glutamate receptors in the postmortem striatum of schizophrenic, suicide, and control brains. Synapse 1997; 27: 168-176
56. Scarr E, Beneyto M, Meador-Woodruff JH, Dean B. Cortical glutamatergic markers in schizophrenia. Neuropsychopharmacology 2005; 30: 1521-1531
57. Huettner J, Bean B. Block of N-methyl-D-Aspartate-Activated current by the anticonvulsant MK-801: Selective binding to open channels. Proc Natl Acad Sci USA 1988; 85: 1307-1311
58. Hillman BG, Gupta SC, Stairs DJ, Buonanno A, Dravid SM. Behavioral analysis of NR2C knockout mouse reveals deficit in acquisition of conditioned fear and working memory. Neurobiol Learn Mem 2011; 95: 404-414
59. Xi D, Keeler B, Zhang W, Houle JD, Gao WJ. NMDA receptor subunit expression in GABAergic interneurons in the prefrontal cortex: Application of laser microdissection technique. J Neurosci Methods 2009; 176: 172-181
60. Fung SJ, Webster MJ, Sivagnanasundaram S, Duncan C, Elashoff M, Weickert CS. Expression of interneuron markers in the dorsolateral prefrontal cortex of the developing human and in schizophrenia. Am J Psychiatry 2010; 167: 1479-1488
61. Beasley CL, Reynolds GP. Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophr Res 1997; 24: 349-355
62. Hashimoto T, Bazmi HH, Mirnics K, Wu Q, Sampson AR, Lewis DA. Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia. Am J Psychiatry 2008; 165: 479-489
63. Hashimoto T, Volk DW, Eggan SM, Mirnics K, Pierri JN, Sun Z et al. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci 2003; 23: 6315-6326
64. Lewis DA, Cruz DA, Melchitzky DS, Pierri JN. Lamina-specific deficits in parvalbumin-immunoreactive varicosities in the prefrontal cortex of subjects with schizophrenia: Evidence for fewer projections from the thalamus. Am J Psychiatry 2001; 158: 1411-1422
65. Morris HM, Hashimoto T, Lewis DA. Alterations in somatostatin mRNA expression in the dorsolateral prefrontal cortex of subjects with schizophrenia or schizoaffective disorder. Cereb Cortex 2008; 18: 1575-1587
66. Reynolds GP, Zhang ZJ, Beasley CL. Neurochemical correlates of cortical GABAergic deficits in schizophrenia: Selective losses of calcium binding protein immunoreactivity. Brain Res Bull 2001; 55: 579-584
67. Zhang ZJ, Reynolds GP. A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia. Schizophr Res 2002; 55: 1-10
68. Carlson R, Khoo B, Yaure R, Schneider W. Acquisition of a problem-solving skill: Levels of organization and use of working memory. J Exp Psychol 1990; 119: 193-214
69. Colom R, Quiroga M, Shih P, Martinez K, Burgaleta M, Martinez-Molina A et al. Improvement in working memory is not related to increased intelligence scores. Intelligence 2010; 38: 497-505
70. de Jong P, de Jong P. Working memory, intelligence, and reading ability in children. Pers Indiv Differ 1996; 21: 1007-1020
71. Kyllonen P, Christal R. Reasoning ability is (little more than) working-memory capacity?! Intelligence 1990; 14: 389-433
72. Unsworth N. On the division of working memory and long-Term memory and their relation to intelligence: A latent variable approach. Acta Psychol 2010; 134: 16-28
73. Unsworth N, Spillers G. Working memory capacity: Attention control, secondary memory or both? A direct test of the dual component model. J Mem Lang 2010; 62: 392-406
74. Lipska BK, Peters T, Hyde TM, Halim N, Horowitz C, Mitkus S et al. Expression of DISC1 binding partners is reduced in schizophrenia and associated with DISC1 SNPs. Hum Mol Genet 2006; 15: 1245-1258
75. Jablensky A, Morar B, Wiltshire S, Carter K, Dragovic M, Badcock JC et al. Polymorphisms associated with normal memory variation also affect memory impairment in schizophrenia. Genes Brain Behav 2011; 10: 410-417